Sintilimab Co-Developed by Innovent Biologics and Lilly Included in China's Updated National Reimbursement Drug List

Suzhou, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (HKEX stock code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative drugs for the treatment of major diseases such as cancer, autoimmune disorders and metabolic diseases, today jointly announced with Eli Lilly and Company that Tyvyt, an innovative PD-1 inhibitor co-developed by the two parties^®(Sintilimab Injection) has been included in Class B of the new edition of the "National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2019 Edition)." According to the official announcement, Tyvyt^®(Sintilimab Injection)The only PD-1 monoclonal antibody successfully included in the National Reimbursement Drug List through medical insurance negotiations this time.。(For details on medical insurance reimbursement and other related information, please refer to the official government announcements.)

Tyvyt®^®(Sintilimab Injection) Its inclusion in the National Reimbursement Drug List (NRDL) demonstrates its recognition by the National Healthcare Security Administration for its clinical value, patient benefits, and degree of innovation. Sintilimab’s inclusion in the updated National Reimbursement Drug List,Further enhance patient access to novel, high-quality immunotherapy drugs.。

Dr. Yu Dechao, Founder, Chairman, and President of Innovent Bio, stated, “In recent years, the nation’s highly effective reforms have advanced the ‘Healthy China’ strategy, continuously safeguarding public health and enhancing well-being. We are deeply grateful to government authorities for the opportunities and recognition afforded to us, which enabled sintilimab injection to become the only PD-1 monoclonal antibody included in the updated National Reimbursement Drug List. Upholding its corporate mission of ‘developing high-quality biologics that are affordable to the general public,’ Innovent Bio will continue to support the deepening of national healthcare security reforms, working collaboratively to improve drug affordability and accessibility, and contributing to the ongoing fulfillment of the people’s growing needs for a better life.”

Ji Liwen, President and General Manager of Eli Lilly China, stated:“Tyvyt®^®(Sintilimab Injection) is the first fruit of the strategic cooperation between Eli Lilly and Innovent Bio. Its launch in the first half of this year has brought innovative immuno-oncology treatment options to numerous patients. Furthermore, its inclusion in the National Reimbursement Drug List through negotiations has not only improved drug accessibility but also further reduced the financial burden on patients. In the future, we will continue to deepen our collaboration with Innovent Bio and join forces with all stakeholders to benefit Chinese patients through multiple dimensions, including innovative drugs, medical services, and payment solutions.”

Mr. Liu Min, Chief Commercial Officer of Innovent Bio and General Manager of Innovent Bio’s Shanghai Branch, stated, “We believe that Tyvyt^®(Sintilimab Injection) Following its inclusion in the National Reimbursement Drug List, it will further alleviate the financial burden on cancer patients and help more patients access long-term, standardized pharmacological treatment. We will continue to actively respond to the relevant initiatives of government authorities at all levels, facilitate the implementation of medical insurance policies across various pooling regions, and accelerate hospital market access. Furthermore, we will persist in collaborating with multiple stakeholders to explore innovative payment models, striving to ensure that more patients can benefit from the health advancements driven by scientific progress.”

Tyvyt®^®(Recombinant fully human anti-PD-1 monoclonal antibody, international trademark: Tyvyt^®, chemical generic name: sintilimab injection) is an innovative PD-1 inhibitor jointly developed by Eli Lilly and Innovent Bio. It was officially approved by the National Medical Products Administration on December 24, 2018, for the treatment of relapsed or refractory classical Hodgkin lymphoma in patients who have undergone at least two lines of systemic chemotherapy.